Olink Bioscience contributes in situ PLA Technology to Colorectal Cancer Project | GenomeWeb

This story originally ran on Sept. 14.

Swedish protein detection and analysis firm Olink Bioscience and its sister company, Olink Genomics, today announced their participation in a project to improve the survival rate of patients with colorectal cancer.

The project, called "Companion Diagnostics Initiative" is financed by the Swedish Governmental Agency for Innovation Systems. The amount of funding was not disclosed. Mats Nilsson, a professor in genetics and pathology at Uppsala University is coordinating the project.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.